Edition:
United Kingdom

People: Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

8.70USD
17 Sep 2019
Change (% chg)

$-0.10 (-1.14%)
Prev Close
$8.80
Open
$8.76
Day's High
$8.85
Day's Low
$8.45
Volume
43,549
Avg. Vol
84,068
52-wk High
$14.77
52-wk Low
$6.71

Henney, Christopher 

Dr. Christopher S. Henney, Ph.D., is Independent Director of Prothena Corporation plc., since March 2013. He is Vice-Chairman of the Board of Cyclacel Pharmaceuticals, Inc. and a member of the Board of Anthera Pharmaceuticals, Inc. From 1995 to 2004, Dr. Henney served as Chairman of the Board and Chief Executive Officer of Dendreon Corporation, a biotechnology company that he co-founded. He also co-founded and served as a director and in executive positions at both Immunex Corporation and ICOS Corporation. Dr. Henney was Chairman of the Board of Cascadian Therapeutics, Inc. (a biotechnology company) from 2006 to 2018, where he also served as interim President and Chief Executive Officer for part of 2016. He is a 2011 inductee to The Biotechnology Hall of Fame. Dr. Henney earned his B.Sc. in medical biochemistry, his Ph.D. in experimental pathology and his D.Sc. for contributions to the field of immunology from the University of Birmingham, England. He has served on our Board since 2013.

Basic Compensation

Total Annual Compensation, USD 70,308
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 435,067
Fiscal Year Total, USD 505,375

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

526,938

Gene Kinney

5,148,240

Tran Nguyen

3,260,720

Karin Walker

--

Wagner Zago

--

Carol Karp

3,880,840
As Of  31 Dec 2017